Skip to content

Ayurvedic treatment for madhumeha (diabetes mellitus)

MULTI MODAL AYURVEDIC TREATMENT OF MADHUMEHA (With particular reference to TYPE 2 DIABETES MELLITUS)

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2015/11/006362
Enrollment
10
Registered
2015-11-16
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Confirmed diagnosis of type 2 Diabetes Mellitus

Interventions

Intervention1: Multi herbal ayurvedic therapy in multiple phases: Mrudu virechana, Niruha basti , Jambubeeja ghanavati containing jambu seeds

Sponsors

P D Patel Ayurveda Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1 Clinical features of madhumeha (type 2 diabetes mellitus) as mentioned in diagnostic criteria. 2 Patient between the ages of 25 to 65 years. 3 Patients with fasting venous glucose 127 to 170mg/dl or postprandial venous glucose 200 to 300 mg/dl. 4 Patients suitable for virecana (according to cha.si. 2/13) and basti (according to cha.si. 2/16).

Exclusion criteria

Exclusion criteria: 1. Patients with associated diseases like cancer, tuberculosis, severe cardiovascular disease. 2. Patients having complications of diabetes like nephropathy, retinopathy,diabetic foot, carbuncles. 3. Patients having diabetes in association with other endocrinopathies likephaeochromocytoma, acromegaly, cushingâ??s syndrome, hyperthyroidism. ï?´ï?®ï? Patients having drug or chemical induced Type 2 diabetes mellitus, likeglucocorticoids induced or thyroid hormone induced. ï?µï?®ï? Patients with genetic syndromes associated with Type 2 diabetes mellitus likeDownâ??s syndrome, klinefelterâ??s syndrome, Turnerâ??s syndrome. 6. Patients of age less than 25 and more than 65 years. 7. Patients dependent on insulin. 8. Patients not suitable for virecana (according to cha.si.2/11) and basti (according to cha.si.2/14). 9. Pregnant and lactating women.

Design outcomes

Primary

MeasureTime frame
Notify improvement in signs and symptoms and laboratory investigations in the patientsTimepoint: Changes in the grade score of signs and symptoms after completion of treatment in comparison of before treatment

Secondary

MeasureTime frame
NilTimepoint: Nil

Countries

India

Contacts

Public ContactDr Rachana Gandhi

J S Ayurveda Mahavidyalaya

guptayurveda@yahoo.com02682520724

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026